Skip to content
ppharmaranks
Menu
CompaniesProductsDrug classesConditionsBest by conditionTreatmentsInteraction checkerFood & medicinesWhat pharmacies payPill identifierMedicines & breastfeedingChildren’s dosage chartsDo medicines expire?Crushing & splitting pillsHow long meds take to workAlternating Tylenol & ibuprofenDrug recallsSupplementsSafety & lawsuitsGuidesA–ZHow we rate

Small Interfering RNA drugs compared

Compare all 2 Small Interfering RNA drugs side by side, used for conditions such as polyneuropathies, amyloid neuropathies, familial. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.

Full ranking · 2 drugs

  1. 1

    amvuttra

    Vutrisiran Sodium

    New
  2. 2

    onpattro

    Patisiran Sodium

    New

Frequently asked questions

What is the Small Interfering RNA drug class?

Small Interfering RNA is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 2 Small Interfering RNA products, each independently rated.

Are all Small Interfering RNA drugs the same?

No. Small Interfering RNA drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do Small Interfering RNA drugs treat?

Per NIH RxClass drug-classification data, Small Interfering RNA drugs are used for conditions including polyneuropathies, amyloid neuropathies, familial.

Sources: the Small Interfering RNA class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.